Last $46.74 USD
Change Today 0.00 / 0.00%
Volume 0.0
GIFLF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Continuous
Continuous
Frankfurt
Frankfurt
As of 8:10 PM 08/25/14 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (GIFLF) Snapshot

Open
$46.74
Previous Close
$46.74
Day High
$46.74
Day Low
$46.74
52 Week High
03/7/14 - $57.50
52 Week Low
10/9/13 - $39.45
Market Cap
15.1B
Average Volume 10 Days
317.2
EPS TTM
--
Shares Outstanding
213.1M
EX-Date
06/5/14
P/E TM
--
Dividend
$0.21
Dividend Yield
0.59%
Current Stock Chart for GRIFOLS SA (GIFLF)

Related News

No related news articles were found.

grifols sa (GIFLF) Related Businessweek News

No Related Businessweek News Found

grifols sa (GIFLF) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

12,649 Employees
Last Reported Date: 07/31/14
Founded in 1940

grifols sa (GIFLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (GIFLF) Key Developments

Grifols Announces Sales Results for the First Half of 2014

Grifols announced sales results for the first half of 2014. For the period, the company reported revenue of EUR 224.8 million. The financial results show Grifols achieving a 23% year-on-year increase in revenues, climbing from EUR 182.8 million. Higher sales volumes in all divisions contributed to overall revenue growth.

Grifols, S.A. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Grifols, S.A. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net revenue of EUR 812,782,000 against EUR 697,143,000 for the same period in the last year. Operating results were EUR 193,470,000 against EUR 192,959,000 for the same period in the last year. Profit before tax was EUR 134,203,000 against EUR 134,990,000 for the same period in the last year. Profit after income tax from continuing operations was EUR 103,336,000 against EUR 90,888,000 for the same period in the last year. Profit attributable to equity holders of the parent was EUR 103,862,000 or EUR 0.30 per diluted share against EUR 91,798,000 or EUR 0.27 per diluted share for the same period in the last year. For the six months, the company reported net revenue of EUR 1,610,780,000 against EUR 1,380,841,000 for the same period in the last year. Operating results were EUR 417,334,000 against EUR 380,363,000 for the same period in the last year. Profit before tax was EUR 289,573,000 against EUR 260,278,000 for the same period in the last year. Profit after income tax from continuing operations was EUR 222,971,000 against EUR 180,435,000 for the same period in the last year. Profit attributable to equity holders of the parent was EUR 224,835,000 or EUR 0.65 per diluted share against EUR 182,800,000 or EUR 0.54 per diluted share for the same period in the last year. Net cash from operating activities was EUR 400,515,000 against EUR 280,261,000 for the same period in the last year. Property, plant and equipment and intangible assets were EUR 143,178,000 against EUR 69,352,000 for the same period in the last year.

Grifols, S.A. to Report First Half, 2014 Results on Jul 31, 2014

Grifols, S.A. announced that they will report first half, 2014 results on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIFLF:US $46.74 USD 0.00

GIFLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $120.26 USD +0.19
Endo International PLC $63.71 USD -0.31
Hospira Inc $53.74 USD -0.48
Stada Arzneimittel AG €30.34 EUR -0.01
UCB SA €73.43 EUR -0.27
View Industry Companies
 

Industry Analysis

GIFLF

Industry Average

Valuation GIFLF Industry Range
Price/Earnings 30.3x
Price/Sales 4.0x
Price/Book 5.2x
Price/Cash Flow 18.7x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.